An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review.

OBJECTIVE: Silexan is a lavender oil preparation in gelatine capsules containing 80 mg. We reviewed the clinical trials investigating the anxiolytic efficacy and tolerability of Silexan as well as its safety and potential for drug interactions. METHODS: Seven trials were included, among which four therapeutic trials had a treatment duration of 6 or 10 weeks. RESULTS: In patients with subsyndromal anxiety or generalised anxiety disorder (GAD) an anxiolytic effect of Silexan was evident after 2 weeks. Patients treated with Silexan showed Hamilton Anxiety Scale (HAMA) total score decreases between 10.4 ± 7.1 and 12.0 ± 7.2 points at Week 6 and between 11.8 ± 7.7 and 16.0 ± 8.3 points at Week 10. CONCLUSIONS: HAMA total score reductions between baseline and end of treatment were significantly superior to placebo in patients with subsyndromal anxiety and comparable to lorazepam in its starting dose in patients with GAD. Silexan had beneficial effects on typical co-morbidity symptoms of anxiety disorders, for example, disturbed sleep, somatic complaints, or decreased quality of life. Except for mild gastrointestinal symptoms, the drug was devoid of adverse effects and did not cause drug interactions or withdrawal symptoms at daily doses of 80 or 160 mg.

Sodium bicarbonate supplementation and ingestion timing: does it matter?

Although a considerable amount of literature exists on the ergogenic potential of ingesting sodium bicarbonate (NaHCO3) before short-term, high-intensity exercise, very little exists on optimal loading times before exercise. The purpose of this study was to determine the influence of NaHCO3 supplementation timing on repeated sprint ability (RSA). Eight men completed 3 (randomized and counterbalanced) trials of ten 10-second sprints separated by 50 seconds of active recovery (1:5 work-to-rest) on a nonmotorized treadmill. Before each trial, the subjects ingested 0.3 g·kg(-1) body weight of NaHCO3 at 60 (H1), 120 (H2), or 180 (H3) minutes before exercise. Additionally, the subjects were assessed for any side effects (gastrointestinal [GI] discomfort) from the NaHCO3 ingestion via a visual analog scale (VAS). Blood buffering was assessed using a 2-way analysis of variance (ANOVA) with repeated measures, whereas repeated sprint performance and GI discomfort were assessed via a 1-way ANOVA with repeated measures. Blood-buffering capacity was not different at preexercise times (HCO3(-) [millimoles per liter] H1: 30.2 ± 0.4, H2: 30.9 ± 0.6, H3: 31.2 ± 0.6; p > 0.74). Average speed, average power, and total distance covered progressively declined over the 10 sprints; however, there was no difference between conditions (p > 0.22). The incidence of GI discomfort was significantly higher (p < 0.05) from preingestion at all time points with the exception of 180 minutes, whereas severity was only different between 90 and 180 minutes. Ingestion times (between 60 and 180 minutes) did not influence the blood buffering or the ergogenic potential of NaHCO3 as assessed by RSA. However, VAS scores indicated that at 180 minutes postingestion, an individual is less prone to experiencing significant GI discomfort.

Effects of garlic oil on platelet aggregation: a double-blind placebo-controlled crossover study.

The use of antiplatelet therapies decreases the incidence of mortality in persons prone to cardiovascular events. Several in vitro studies suggest that garlic may decrease platelet aggregation. We aimed to test the acute effects of garlic on platelet aggregation in 14 healthy volunteers using a randomised, double-blind, placebo-controlled, crossover research method. The active agent tested was solvent-extracted garlic oil incubated in ethanol to obtain organosulphur compounds that demonstrate the highest antiplatelet activity when tested in vitro. Platelet aggregation was induced ex vivo by adrenaline, collagen or adenosine diphosphate (ADP). Four hours after consuming one large dose of oil derived from 9.9 g garlic, there was little or no effect in the reduction of platelet aggregation. Platelet aggregation induced by adrenaline was reduced slightly but significantly (P<0.05; 12% reduction). The oil had no effect on collagen- or ADP-induced aggregation. The results of this controlled trial indicate that this type of garlic oil should not be relied on in persons with conditions in which reductions in platelet aggregation are desired or necessary.